Advancing the global public health agenda for NAFLD: a consensus statement
Tóm tắt
Từ khóa
Tài liệu tham khảo
Golabi, P. et al. Non-alcoholic fatty liver disease (NAFLD) is associated with impairment of health related quality of life (HRQOL). Health Qual. Life Outcomes 14, 18 (2016).
McSweeney, L. et al. Health-related quality of life and patient-reported outcome measures in NASH-related cirrhosis. JHEP Rep. 2, 100099 (2020).
O’Hara, J. et al. Cost of non-alcoholic steatohepatitis in Europe and the USA: the GAIN study. JHEP Rep. 2, 100142 (2020).
Schattenberg, J. M. et al. Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis (NASH) in five European countries in 2018: a cost-of-illness analysis. Liver Int. 41, 1227–1242 (2021).
Younossi, Z. M. et al. The association of histologic and noninvasive tests with adverse clinical and patient-reported outcomes in patients with advanced fibrosis due to nonalcoholic steatohepatitis. Gastroenterology https://doi.org/10.1053/j.gastro.2020.12.003 (2020).
Younossi, Z. M. et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology 64, 1577–1586 (2016).
Hagström, H. et al. Health care costs of patients with biopsy-confirmed nonalcoholic fatty liver disease are nearly twice those of matched controls. Clin. Gastroenterol. Hepatol. 18, 1592–1599.e8 (2020).
Gordon, S. C., Fraysse, J., Li, S., Ozbay, A. B. & Wong, R. J. Disease severity is associated with higher healthcare utilization in nonalcoholic steatohepatitis Medicare patients. Am. J. Gastroenterol. 115, 562–574 (2020).
Bertot, L. C. & Adams, L. A. The natural course of non-alcoholic fatty liver disease. Int. J. Mol. Sci. 17, 774 (2016).
Ekstedt, M., Nasr, P. & Kechagias, S. Natural history of NAFLD/NASH. Curr. Hepatol. Rep. 16, 391–397 (2017).
Araújo, A. R., Rosso, N., Bedogni, G., Tiribelli, C. & Bellentani, S. Global epidemiology of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: what we need in the future. Liver Int. 38, 47–51 (2018).
Kanwal, F. et al. Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease. Gastroenterology 155, 1828–1837.e2 (2018).
Haldar, D. et al. Outcomes of liver transplantation for non-alcoholic steatohepatitis: a European Liver Transplant Registry study. J. Hepatol. 71, 313–322 (2019).
Terrault, N. A. & Pageaux, G.-P. A changing landscape of liver transplantation: king HCV is dethroned, ALD and NAFLD take over! J. Hepatol. 69, 767–768 (2018).
Global Burden of Disease Cancer Collaboration et al.Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol. 5, 1749–1768 (2019).
Adams, L. A., Anstee, Q. M., Tilg, H. & Targher, G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 66, 1138–1153 (2017).
Anstee, Q. M., Targher, G. & Day, C. P. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat. Rev. Gastroenterol. Hepatol. 10, 330–344 (2013).
Albhaisi, S., Chowdhury, A. & Sanyal, A. J. Non-alcoholic fatty liver disease in lean individuals. JHEP Rep.: Innov. Hepatol. 1, 329–341 (2019).
Younossi, Z. et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 15, 11–20 (2018).
Vilar-Gomez, E. et al. Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study. Gastroenterology 155, 443–457.e17 (2018).
Angulo, P. et al. Liver fibrosis, but no other histologic features, is asssociated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 149, 389–397.e10 (2015).
Haflidadottir, S. et al. Long-term follow-up and liver-related death rate in patients with non-alcoholic and alcoholic related fatty liver disease. BMC Gastroenterol. 14, 166 (2014).
Park, S. K., Seo, M. H., Shin, H. C. & Ryoo, J. H. Clinical availability of nonalcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in Korean men: 5-year prospective cohort study. Hepatology 57, 1378–1383 (2013).
World Health Organization. Global action plan for the prevention and control of noncommunicable diseases 2013–2020. WHO https://apps.who.int/iris/bitstream/handle/10665/94384/9789241506236_eng.pdf (2013).
Bennett, J. E. et al. NCD countdown 2030: worldwide trends in non-communicable disease mortality and progress towards Sustainable Development Goal target 3.4. Lancet 392, 1072–1088 (2018).
Rotondi, A. & Gustafson, D. in Gazing into the Oracle: The Delphi Method and its Application to Social Policy and Public Health (eds Adler, M. & Ziglio, E.) 34–55 (Jessica Kingsley, 1996).
Rubino, F. et al. Joint international consensus statement for ending stigma of obesity. Nat. Med. 26, 485–497 (2020).
Lazarus, J. V. et al. Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV. Nat. Commun. 12, 4450 (2021).
Vos, T. et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 396, 1204–1222 (2020).
Younossi, Z. M. et al. Global epidemiology of nonalcoholic fatty liver disease–meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64, 73–84 (2016).
Estes, C. et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J. Hepatol. 69, 896–904 (2018).
Estes, C., Razavi, H., Loomba, R., Younossi, Z. & Sanyal, A. J. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology 67, 123–133 (2018).
Younossi, Z. et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology 69, 2672–2682 (2019).
Ye, Q. et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 5, 739–752 (2020).
Bjorkstrom, K., Stal, P., Hultcrantz, R. & Hagstrom, H. Histologic scores for fat and fibrosis associate with development of type 2 diabetes in patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 15, 1461–1468 (2017).
Musso, G., Gambino, R., Cassader, M. & Pagano, G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann. Med. 43, 617–649 (2011).
Sepanlou, S. G. et al. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol. Hepatol. 5, 245–266 (2020).
Anderson, E. L. et al. The prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis. PLoS ONE 10, e0140908 (2015).
Jimenez-Rivera, C. et al. Prevalence and risk factors for non-alcoholic fatty liver in children and youth with obesity. BMC Pediatr. 17, 113 (2017).
Xanthakos, S. A. et al. High prevalence of nonalcoholic fatty liver disease in adolescents undergoing bariatric surgery. Gastroenterology 149, 623–634.e8 (2015).
Yu, E. L. et al. Prevalence of nonalcoholic fatty liver disease in children with obesity. J. Pediatr. 207, 64–70 (2019).
Schwimmer, J. B. et al. Prevalence of fatty liver in children and adolescents. Pediatrics 118, 1388–1393 (2006).
Yüksel, F. et al. Fatty liver disease in an autopsy series of children and adolescents. Hippokratia 16, 61–65 (2012).
Rocha, R. et al. Nonalcoholic fatty liver disease in asymptomatic Brazilian adolescents. World J. Gastroenterol. 15, 473–477 (2009).
Zhang, X. et al. Increasing prevalence of NAFLD/NASH among children, adolescents and young adults from 1990 to 2017: a population-based observational study. BMJ Open 11, e042843 (2021).
Schwimmer, J. B. et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 42, 641–649 (2005).
Nobili, V. et al. NAFLD in children: new genes, new diagnostic modalities and new drugs. Nat. Rev. Gastroenterol. Hepatol. 16, 517–530 (2019).
Vos, M. B. et al. Factors to consider in development of drugs for pediatric nonalcoholic fatty liver disease. Gastroenterology 157, 1448–1456.e1 (2019).
Nadeau, K. J. et al. Youth-onset type 2 diabetes consensus report: current status, challenges, and priorities. Diabetes Care 39, 1635–1642 (2016).
Zimmermann, E. et al. Body mass index in school-aged children and the risk of routinely diagnosed non-alcoholic fatty liver disease in adulthood: a prospective study based on the Copenhagen School Health Records Register. BMJ Open 5, e006998 (2015).
Berentzen, T. L., Gamborg, M., Holst, C., Sørensen, T. I. & Baker, J. L. Body mass index in childhood and adult risk of primary liver cancer. J. Hepatol. 60, 325–330 (2014).
Hagström, H., Stål, P., Hultcrantz, R., Hemmingsson, T. & Andreasson, A. Overweight in late adolescence predicts development of severe liver disease later in life: a 39years follow-up study. J. Hepatol. 65, 363–368 (2016).
Hagström, H., Tynelius, P. & Rasmussen, F. High BMI in late adolescence predicts future severe liver disease and hepatocellular carcinoma: a national, population-based cohort study in 1.2 million men. Gut 67, 1536–1542 (2018).
Simon, T. G. et al. Non-alcoholic fatty liver disease in children and young adults is associated with increased long-term mortality. J. Hepatol. https://doi.org/10.1016/j.jhep.2021.06.034 (2021).
Younossi, Z. M. et al. A disease-specific quality of life instrument for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: CLDQ-NAFLD. Liver Int. 37, 1209–1218 (2017).
Doward, L. C. et al. Development of a patient-reported outcome measure for non-alcoholic steatohepatitis (NASH-CHECK): results of a qualitative study. Patient 14, 533–543 (2021).
Twiss, J. et al. Development of a new patient-reported outcome measure for non-alcoholic steatohepatitis: NASH-CHECK [abstract PGI39]. Value Health 20, A638 (2017).
Huber, Y. et al. Health-related quality of life in nonalcoholic fatty liver disease associates with hepatic inflammation. Clin. Gastroenterol. Hepatol. 17, 2085–2092.e1 (2019).
David, K. et al. Quality of life in adults with nonalcoholic fatty liver disease: baseline data from the Nonalcoholic Ateatohepatitis Clinical Research Network. Hepatology 49, 1904–1912 (2009).
Kennedy-Martin, T., Bae, J. P., Paczkowski, R. & Freeman, E. Health-related quality of life burden of nonalcoholic steatohepatitis: a robust pragmatic literature review. J. Patient Rep. Outcomes 2, 28 (2017).
Casey, J. A., Schwartz, B. S., Stewart, W. F. & Adler, N. E. Using electronic health records for population health research: a review of methods and applications. Annu. Rev. Public Health 37, 61–81 (2016).
Hagström, H. et al. Administrative coding in electronic health care record-based research of NAFLD: an expert panel consensus statement. Hepatology https://doi.org/10.1002/hep.31726 (2021).
Sanyal, A. J. Putting non-alcoholic fatty liver disease on the radar for primary care physicians: how well are we doing? BMC Med. 16, 148 (2018).
Bergqvist, C. J. et al. Awareness and opinions of non-alcoholic fatty liver disease by hospital specialists. Intern. Med. J. 43, 247–253 (2013).
Alemany-Pagès, M. et al. Insights from qualitative research on NAFLD awareness with a cohort of T2DM patients: time to go public with insulin resistance? BMC Public Health 20, 1142–1142 (2020).
Wieland, A. C. et al. Low awareness of nonalcoholic fatty liver disease among patients at high metabolic risk. J. Clin. Gastroenterol. 49, e6–e10 (2015).
Goh, G. B. B. et al. Perceptions of non-alcoholic fatty liver disease – an Asian community-based study. Gastroenterol. Rep. 4, 131–135 (2016).
Ghevariya, V. et al. Knowing what’s out there: awareness of non-alcoholic fatty liver disease. Front. Med. 1, 4 (2014).
Augustin, S., Pons, M., Santos, B., Ventura, M. & Genescà, J. in Portal Hypertension VI: Proceedings of the Sixth Baveno Consensus Workshop: Stratifying Risk and Individualizing Care (ed. de Franchis, R.) 39–49 (Springer, 2016).
de Franchis, R. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: Stratifying Risk and Individualizing Care for Portal Hypertension. J. Hepatol. 63, 743–752 (2015).
Lazarus, J. V. et al. We know DAAs work, so now what? Simplifying models of care to enhance the hepatitis C cascade. J. Intern. Med. 286, 503–525 (2019).
Lazarus, J. V. et al. Defining comprehensive models of care for NAFLD. Nat. Rev. Gastroenterol. Hepatol. https://doi.org/10.1038/s41575-021-00477-7 (2021).
Grgurevic, I. et al. Natural history of nonalcoholic fatty liver disease: implications for clinical practice and an individualized approach. Can. J. Gastroenterol. Hepatol. 2020, 9181368 (2020).
Dyson, J. K., Anstee, Q. M. & McPherson, S. Non-alcoholic fatty liver disease: a practical approach to treatment. Frontline Gastroenterol. 5, 277–286 (2014).
Ruissen, M. M., Mak, A. L., Beuers, U., Tushuizen, M. E. & Holleboom, A. G. Non-alcoholic fatty liver disease: a multidisciplinary approach towards a cardiometabolic liver disease. Eur. J. Endocrinol. 183, R57–R73 (2020).
Ahmed, M. H., Woodward, C. & Mital, D. Metabolic clinic for individuals with HIV/AIDS: a commitment and vision to the future of HIV services. Cardiovasc. Endocrinol. 6, 109–112 (2017).
Armstrong, M. J. et al. Severe asymptomatic non-alcoholic fatty liver disease in routine diabetes care; a multi-disciplinary team approach to diagnosis and management. QJM 107, 33–41 (2014).
DeVore, S. et al. A multidisciplinary clinical program is effective in stabilizing BMI and reducing transaminase levels in pediatric patients with NAFLD. J. Pediatr. Gastroenterol. Nutr. 57, 119–123 (2013).
Moolla, A. et al. A multidisciplinary approach to the management of NAFLD is associated with improvement in markers of liver and cardio-metabolic health. Frontline Gastroenterol. 10, 337–346 (2019).
Neilson, L. J. et al. Implementation of a care bundle improves the management of patients with non-alcoholic fatty liver disease. Frontline Gastroenterol. https://doi.org/10.1136/flgastro-2020-101480 (2021).
Dyson, J. K., Anstee, Q. M. & McPherson, S. Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. Front. Gastroenterol. 5, 211–218 (2014).
Chalmers, J. et al. The development and implementation of a commissioned pathway for the identification and stratification of liver disease in the community. Front. Gastroenterol. 11, 86–92 (2020).
Dillon, J. F. et al. Intelligent liver function testing (iLFT): a trial of automated diagnosis and staging of liver disease in primary care. J. Hepatol. 71, 699–706 (2019).
Hudson, M. & McPherson, S, on behalf of the North East & North Cumbria Hepatology Network. Liver Network: Guidelines for the Management of Adults with Asymptomatic Liver Function Abnormalities (Northern England Clinical Strategic Networks, 2020).
Shaheen, A. A. et al. Risk stratification of patients with nonalcoholic fatty liver disease using a case identification pathway in primary care: a cross-sectional study. CMAJ Open 8, E370–E376 (2020).
Srivastava, A. et al. Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. J. Hepatol. 71, 371–378 (2019).
Crossan, C. et al. Referral pathways for patients with NAFLD based on non-invasive fibrosis tests: diagnostic accuracy and cost analysis. Liver Int. 39, 2052–2060 (2019).
Srivastava, A. et al. Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease. BMC Gastroenterol. 19, 122 (2019).
Tanajewski, L. et al. Economic evaluation of a community-based diagnostic pathway to stratify adults for non-alcoholic fatty liver disease: a Markov model informed by a feasibility study. BMJ Open 7, e015659 (2017).
Alexander, M. et al. Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease. BMC Med. 16, 130 (2018).
Cooke, G. S. et al. Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol. Hepatol. 4, 135–184 (2019).
Mencin, A. A., Loomba, R. & Lavine, J. E. Caring for children with NAFLD and navigating their care into adulthood. Nat. Rev. Gastroenterol. Hepatol. 12, 617–628 (2015).
Taylor, R. S. et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterology 158, 1611–1625.e12 (2020).
Castera, L., Friedrich-Rust, M. & Loomba, R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology 156, 1264–1281.e4 (2019).
Vali, Y. et al. Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: a systematic review and meta-analysis. J. Hepatol. 73, 252–262 (2020).
McPherson, S. et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. Am. J. Gastroenterol. 112, 740–751 (2017).
Anstee, Q. M. et al. Noninvasive tests accurately identify advanced fibrosis due to NASH: baseline data from the STELLAR trials. Hepatology 70, 1521–1530 (2019).
Augustin, S. et al. Identification of patients with advanced fibrosis due to nonalcoholic fatty liver disease: considerations for best practice. J. Gastrointestin Liver Dis. 29, 235–245 (2020).
Castera, L. Diagnosis of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: non-invasive tests are enough. Liver Int. 38(Suppl 1), 67–70 (2018).
Majumdar, A., Campos, S., Gurusamy, K., Pinzani, M. & Tsochatzis, E. A. Defining the minimum acceptable diagnostic accuracy of noninvasive fibrosis testing in cirrhosis: a decision analytic modeling study. Hepatology 71, 627–642 (2020).
Jung, J. et al. MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis. Gut 70, 1946–1953 (2021).
Mosca, A., Panera, N., Crudele, A. & Alisi, A. Noninvasive diagnostic tools for pediatric NAFLD: where are we now? Expert Rev. Gastroenterol. Hepatol. 14, 1035–1046 (2020).
Di Cesare, M. et al. Inequalities in non-communicable diseases and effective responses. Lancet 381, 585–597 (2013).
Peters, R. et al. Common risk factors for major noncommunicable disease, a systematic overview of reviews and commentary: the implied potential for targeted risk reduction. Ther. Adv. Chronic Dis. 10, 2040622319880392–2040622319880392 (2019).
Fuchs, S., Henschke, C., Blümel, M. & Busse, R. Disease management programs for type 2 diabetes in Germany: a systematic literature review evaluating effectiveness. Dtsch. Arztebl Int. 111, 453–463 (2014).
World Health Organization. WHO package of essential noncommunicable (PEN) disease interventions for primary health care. WHO https://www.who.int/publications/i/item/who-package-of-essential-noncommunicable-(pen)-disease-interventions-for-primary-health-care (2020).
Dixon, B. E., Embi, P. J. & Haggstrom, D. A. Information technologies that facilitate care coordination: provider and patient perspectives. Transl. Behav. Med. 8, 522–525 (2018).
Ando, Y. & Jou, J. H. Nonalcoholic fatty liver disease and recent guideline updates. Clin. Liver Dis. 17, 23–28 (2021).
Leoni, S. et al. Current guidelines for the management of non-alcoholic fatty liver disease: a systematic review with comparative analysis. World J. Gastroenterol. 24, 3361–3373 (2018).
European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO) EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 64, 1388–1402 (2016).
Arab, J. P. et al. Latin American Association for the Study of the Liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease. Ann. Hepatol. 19, 674–690 (2020).
Chalasani, N. et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67, 328–357 (2018).
Chitturi, S. et al. The Asia–Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017–Part 2: Management and special groups. J. Gastroenterol. Hepatol. 33, 86–98 (2018).
Eslam, M. et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol. Int. 14, 889–919 (2020).
Muthiah, M. D. & Sanyal, A. J. Current management of non-alcoholic steatohepatitis. Liver Int. 40 (Suppl. 1), 89–95 (2020).
Hallsworth, K. & Adams, L. A. Lifestyle modification in NAFLD/NASH: facts and figures. JHEP Rep. Innov. Hepatol. 1, 468–479 (2019).
Romero-Gómez, M., Zelber-Sagi, S. & Trenell, M. Treatment of NAFLD with diet, physical activity and exercise. J. Hepatol. 67, 829–846 (2017).
Jensen, M. D. et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation 129, S102–S138 (2014).
Hydes, T. J., Ravi, S., Loomba, R. & Gray, M. E. Evidence-based clinical advice for nutrition and dietary weight loss strategies for the management of NAFLD and NASH. Clin. Mol. Hepatol. 26, 383–400 (2020).
Geurtsen, M. L., Santos, S., Gaillard, R., Felix, J. F. & Jaddoe, V. W. V. Associations between intake of sugar-containing beverages in infancy with liver fat accumulation at school age. Hepatology 73, 560–570 (2021).
Berná, G. & Romero-Gomez, M. The role of nutrition in non-alcoholic fatty liver disease: pathophysiology and management. Liver Int. 40 (Suppl. 1), 102–108 (2020).
Hashida, R. et al. Aerobic vs resistance exercise in non-alcoholic fatty liver disease: a systematic review. J. Hepatol. 66, 142–152 (2017).
Lazarus, J. V. et al. A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe. J. Hepatol. 72, 14–24 (2020).
Neuschwander-Tetri, B. A. Therapeutic landscape for NAFLD in 2020. Gastroenterology 158, 1984–1998.e3 (2020).
Wong, E. L. Y. et al. Patient experience and satisfaction with inpatient service: development of short form survey instrument measuring the core aspect of inpatient experience. PLoS ONE 10, e0122299 (2015).
Martin, L. R., Williams, S. L., Haskard, K. B. & Dimatteo, M. R. The challenge of patient adherence. Ther. Clin. Risk Manag. 1, 189–199 (2005).
World Health Assembly. Hepatitis. WHO https://apps.who.int/gb/ebwha/pdf_files/WHA67/A67_R6-en.pdf?ua=1 (2014).
Puhl, R. M. & Heuer, C. A. Obesity stigma: important considerations for public health. Am. J. Public Health 100, 1019–1028 (2010).
Vaughn-Sandler, V., Sherman, C., Aronsohn, A. & Volk, M. L. Consequences of perceived stigma among patients with cirrhosis. Dig. Dis. Sci. 59, 681–686 (2014).
Himmelstein, M. S. & Puhl, R. M. At multiple fronts: diabetes stigma and weight stigma in adults with type 2 diabetes. Diabet. Med. 38, e14387 (2021).
Lazarus, J. V. et al. European ‘NAFLD Preparedness Index’–is Europe ready to meet the challenge of fatty liver disease? JHEP Rep. 3, 100234 (2021).
Lazarus, J. V. et al. The global non-alcoholic fatty liver disease (NAFLD) preparedness index: are countries ready to tackle the challenge? Int. Liver Congr. 75 (Suppl. 2), 23–26 (2021).
NASH Council & Global Liver Institute. U.S NASH action plan (Global Liver Institute, 2020).
World Health Organization. Continuity and coordination of care: a practice brief to support implementation of the WHO Framework on integrated people-centred health services (Alliance for Health Policy and Systems Research, 2018).
Atun, R. et al. Improving responsiveness of health systems to non-communicable diseases. Lancet 381, 690–697 (2013).
Rutter, H. et al. The need for a complex systems model of evidence for public health. Lancet 390, 2602–2604 (2017).
Kumanyika, S., Jeffery, R. W., Morabia, A., Ritenbaugh, C. & Antipatis, V. J. Obesity prevention: the case for action. Int. J. Obes. Relat. Metab. Disord. 26, 425–436 (2002).
Gortmaker, S. L. et al. Changing the future of obesity: science, policy, and action. Lancet 378, 838–847 (2011).
Huang, T. T., Drewnosksi, A., Kumanyika, S. & Glass, T. A. A systems-oriented multilevel framework for addressing obesity in the 21st century. Prev. Chronic Dis. 6, A82 (2009).
Huang, T. & Ferris, E. in Childhood Obesity Ch. 42 (ed. Goran, M. I.) (Taylor and Francis, 2016).
Huang, T. T. et al. Mobilisation of public support for policy actions to prevent obesity. Lancet 385, 2422–2431 (2015).
Lazarus, J. V. et al. A Sustainable Development Goal framework to guide multisectoral action on NAFLD through a societal approach. Preprint at medRxiv https://doi.org/10.1101/2021.08.02.21261464 (2021).
Adler, M. & Ziglio, E. Gazing into the Oracle: The Delphi Method and its Application to Social Policy and Public Health (Jessica Kingsley, 1996).
Grime, M. M. & Wright, G. in Wiley StatsRef: Statistics Reference Online 1–6 (Wiley, 2011).
Targher, G. & Byrne, C. D. From nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease: is it time for a change of terminology? Hepatoma Res. 6, 64 (2020).
Eslam, M. et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J. Hepatol. 73, 202–209 (2020).
Eslam, M., Sanyal, A. J. & George, J. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 158, 1999–2014.e1 (2020).
Mendez-Sanchez, N. et al. The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease. Lancet Gastroenterol. Hepatol. 6, 65–72 (2021).
Spearman, C. W. et al. The sub-Saharan Africa position statement on the redefinition of fatty liver disease: from NAFLD to MAFLD. J. Hepatol. 74, 1256–1258 (2021).
Shiha, G. et al. Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa. Lancet Gastroenterol. Hepatol. 6, 57–64 (2021).
Ratziu, V. et al. The times they are a-changin’ (for NAFLD as well). J. Hepatol. 73, 1307–1309 (2020).
Younossi, Z. M. et al. From NAFLD to MAFLD: implications of a premature change in terminology. Hepatology 73, 1194–1198 (2021).
Wong, V. W. et al. Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017–Part 1: definition, risk factors and assessment. J. Gastroenterol. Hepatol. 33, 70–85 (2018).
American Diabetes Association. Comprehensive medical evaluation and assessment of comorbidities: standards of medical care in diabetes — 2020. Diabetes Care 43, S37–S47 (2020).
World Health Organization. Nothing for us, without us: opportunities for meaningful engagement of people living with NCDs: meeting report (WHO, 2021).